Bellevue Life Sciences Acquisition Corp.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Kuk Hyoun Hwang
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 10900 NE 4th Street Bellevue WA United States of America 98004
- IPO Date
- Mar 21, 2023
- CIK
- 0001840425
- Website
- bellevuespac.com
- Similar Companies
- Business
- Bellevue Life Sciences Acquisition Corp. (Ticker: BLAC) is a publicly traded special purpose acquisition company (SPAC) focused on acquiring and merging with businesses in the life sciences industry. The company primarily targets innovative biopharmaceutical and life sciences companies that develop and commercialize therapeutics or technologies aimed at improving health outcomes. As a SPAC, its core service offering includes raising capital through an initial public offering and subsequently completing strategic mergers or acquisitions with life sciences firms that align with its investment criteria. Bellevue Life Sciences Acquisition Corp. operates primarily in the United States but targets growth-stage companies in the global life sciences sector, including biotechnology, pharmaceuticals, and healthcare technology companies. Founded in 2020, the company is headquartered in New York City. It functions within the broader themes of healthcare and life sciences investment, serving public market investors and emerging life sciences enterprises seeking capital and strategic support. In the most recent developments within the last two years, Bellevue Life Sciences Acquisition Corp. has actively engaged in merger agreements and fundraising rounds to solidify its position in the life sciences investment space. Notably, it completed a de-SPAC transaction with a prominent life sciences business, expanding its portfolio in biopharmaceuticals. The company has also formed strategic partnerships to enhance its deal flow pipeline and access innovative biotech assets, reflecting a strategic expansion in its operational capabilities and market reach. These moves demonstrate a focus on accelerating growth through targeted acquisitions and expanding its footprint in key life sciences sub-sectors. No recent changes in company name or headquarters location have been reported. Overall, Bellevue Life Sciences Acquisition Corp. specializes in providing capital and strategic direction for the life sciences industry through its SPAC platform, focusing on mergers and acquisitions in biotechnology, pharmaceuticals, and healthcare technology. Its recent activities highlight ongoing efforts to grow and diversify its portfolio within the sector, leveraging partnerships and capital markets expertise to drive value creation for investors and life sciences innovators alike.
Bellevue Life Sciences Acquisition (NASDAQ:BLAC) Shares Up 3.5% – Should You Buy?
Bellevue Life Sciences Acquisition (NASDAQ:BLAC) Stock Price Up 13.7% – Time to Buy?
Bellevue Life Sciences Acquisition Corp. Announces Approval of Business Combination Proposal And Name Change to OSR Holdings, Inc.
Bellevue Life Sciences Acquisitions Corp. Reminds Stockholders to Vote in Favor of Extension at May 14, 2024 Stockholder Meeting
OSR Holdings and SillaJen have entered into a Memorandum of Understanding to collaboratively pursue the development of innovative therapeutics and enter the U.S. market
OSR Holdings Co., Ltd. Enters Into Business Combination Agreement with Bellevue Life Sciences Acquisition Corp.
Bellevue Life Sciences Acquisition Corp. and OSR Holdings Sign an Exclusive Letter of Intent for a Business Combination